SLC25A19 and carcinoma: Importantly, high expression of SLC25A19 was observed in 47.2% of CRC tissues but only in 2.9% of para‐carcinoma tissues (Table 1) and was positively associated with age, gender, lymph node positivity, lymph node invasion, stage, and lymphatic metastasis (Tables 2 and 3), implying that the expression of SLC25A19 increased with the degree of malignancy in CRC patients.